Altimmune バランスシートの健全性
財務の健全性 基準チェック /56
Altimmuneの総株主資本は$284.0M 、総負債は$34.5Mで、負債比率は12.2%となります。総資産と総負債はそれぞれ$335.6Mと$51.6Mです。
主要情報
12.15%
負債資本比率
US$34.51m
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$331.54m |
| エクイティ | US$283.99m |
| 負債合計 | US$51.64m |
| 総資産 | US$335.63m |
財務の健全性に関する最新情報
分析記事 • Jan 15
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Sep 12
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, Altimmune ( NASDAQ:ALT...分析記事 • Feb 10
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Oct 11
Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Recent updates
Seeking Alpha • Jul 07
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
Summary Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed statistically significant MASH resolution and fibrosis improvement, but competition from semaglutide, resmetirom, and others remains intense. ALT's near-term catalyst is the Phase 2 AUD data, with potential for partnership if results demonstrate differentiation in heavy drinking reduction and liver outcomes. ALT's investment case hinges on pemvidutide's ability to show clear superiority or unique benefits versus established GLP-1 therapies in upcoming trials. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 26
ALT: Fast Track MASH Program Will Drive Future Upside Potential
Analysts have reset their Altimmune fair value estimate from $17.88 to $15.45, reflecting updated assumptions for the discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for Altimmune Altimmune reported 48 week data from the IMPACT Phase 2b trial of pemvidutide in MASH, with patients on the 1.8 mg dose showing reductions in triglycerides of 23.7% and total cholesterol of 15.4%, along with changes in weight, body mass index, waist circumference and blood pressure versus placebo, while maintaining a generally favorable safety and tolerability profile.Seeking Alpha • Mar 17
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine
Summary Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH] market could reach $39.3 billion by 2031. Company received IND clearance from the FDA to advance two mid-stage studies using pemvidutide to target patients with AUD and ALD; First phase 2 study to start in mid-2025. Pemvidutide is also being developed for patients with obesity; ALT received clearance from the FDA to run four phase 3 studies for possible eventual marketing approval in targeting these patients. Read the full article on Seeking AlphaSeeking Alpha • Feb 28
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2
Summary Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock has stabilized, with recent data showing significant weight loss at higher doses, sparking renewed investor interest. Altimmune's Q4 2024 earnings reveal a net loss of $23.2m, with $131.9m in cash, highlighting the company's ongoing financial challenges and reliance on future clinical success. Investors should watch for the Phase 2b IMPACT study results in Q2 2025, which could significantly impact Altimmune's stock and future prospects in the MASH market. Read the full article on Seeking AlphaSeeking Alpha • Feb 18
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
Summary Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis). Pemvidutide has successfully completed a Phase 1 trial for a related liver disease but has yet to demonstrate efficacy in the target indication of MASH. Direct peers such as Akero Therapeutics and Madrigal have more advanced clinical trials and are valued at $2 billion and $7 billion, respectively, implying significant upside potential for ALT stock. Comparable catalysts for MASH show that Altimmune, with positive Phase 2 data, could experience a market cap expansion of $475 million, equating to an almost 80% upside. Read the full article on Seeking Alpha分析記事 • Jan 15
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Dec 30
Altimmune Could Find A Partner For Its Phase 3 Exercise
Summary ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while at the current rate, but not to fund phase 3, the company needs a partner or a buyout. If ALT can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock. Despite competition, the potential for a partnership or buyout remains strong, as Big Pharma continues to show interest in weight loss drugs, and ALT seems cheap compared to its peers. Read the full article on Seeking AlphaSeeking Alpha • Dec 16
Altimmune 2025: Redefining Obesity And MASH Treatment
Summary Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety profile. Altimmune is redefining success in both obesity and MASH to position Pemvidutide in "blue ocean" categories not addressed by incumbents and catered to the unique strengths of Glucagon in Pemvidutide. Valuation of on-label and off-label use of Pemvidutide across all indications and comorbidities show that Altimmune is significantly undervalued at current share prices, factoring in all risks. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health
Summary Altimmune, Inc.’s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obesity demonstrated significant weight loss and lean mass preservation, with up to 15.6% weight reduction at the highest dose. Altimmune’s cash runway is estimated to support operations into 1H2026, aligning with expected milestones and anticipated Phase 3 trials. The company plans to expand Pemvidutide’s applications with a new IND for additional indications by year-end, enhancing its market potential. Thus, I am upgrading ALT stock to a “Strong Buy” due to the promising progress of its lead drug candidate, sufficient runway, and several future catalysts. Read the full article on Seeking AlphaSeeking Alpha • Oct 28
Regulatory And Clinical Catalysts Ahead For Altimmune
Summary ALT is developing pemvidutide for obesity and liver diseases, with recent MOMENTUM sub-study results showing favorable body composition results. A readout from the Phase 2b trial of pemvidutide in MASH is delayed to Q2'25, although the trial has completed enrollment, making further delays unlikely. ALT has $164.9M in cash but may need additional funding for phase 3 trials; a partnership for phase 3 development in obesity remains a possibility. Read the full article on Seeking AlphaSeeking Alpha • Oct 02
Consider Buying Potential Takeover Target Altimmune
Summary Altimmune, Inc.'s weight loss drug, pemvidutide, shows significant superiority in lean mass retention and liver fat reduction, making it a potential takeover target. High short interest in Altimmune stock could trigger a short-covering rally if reports of takeover talks emerge. Pemvidutide's superior lean mass retention could enable it to capture market share from Novo Nordisk's Wegovy and Eli Lilly's tirzepatide. Read the full article on Seeking AlphaSeeking Alpha • Sep 21
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Summary Pemvidutide shows strong potential in obesity and MASH, preserving lean mass while reducing VAT, which could make it a market leader among GLP-1s. Recent Phase II data reveals pemvidutide's lean loss ratio of 21.9%, comparable to diet and exercise, and significant VAT reduction, enhancing its appeal. Despite competition and risks, I am bullish on ALT, upgrading my conviction rating and planning to add to my position below $8.20 per share. Pemvidutide's dual indications for obesity and MASH, along with potential cardiovascular benefits, could drive Altimmune to blockbuster status and significant revenue growth. Read the full article on Seeking Alpha分析記事 • Sep 12
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, Altimmune ( NASDAQ:ALT...Seeking Alpha • Aug 27
Altimmune: Emerging Position In Competitive Space, But Risks Remain
Summary Weight loss drugs like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide dominate the market, with Novo Nordisk leading in sales and Amgen developing a novel competitor. Altimmune’s pemvidutide shows promising weight loss and lean mass preservation but faces high discontinuation rates and lacks sugar control, unlike rivals. Financially, Altimmune has a cash runway of five to six quarters, necessitating a likely dilution before their phase 3 trial's completion. Despite promising data, Altimmune's pemvidutide faces tough competition from established players, making it a risky investment without more differentiating metrics. Read the full article on Seeking AlphaSeeking Alpha • Jun 24
Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note
Summary Altimmune, Inc. shares surged nearly 30% after positive Phase 2 clinical study results for pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH. Pemvidutide may compete with Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, which have demonstrated miraculous weight loss improvements, and will likely dominate a ~$130bn market. Altimmune's latest data shows significant weight loss and lean muscle preservation - the latter may be most significant. If pemvidutide can show it removes less lean muscle fat than competing GLP-1 agonist drugs, it may be on a fast track to approval and a double-digit billion dollar revenue opportunity. It is not quite so simple as it sounds, however - other candidates are yet to fully show their hands, and Altimmune is a minnow compared to the large pharmas crowding this space. Nevertheless, it is an interesting development. Read the full article on Seeking AlphaSeeking Alpha • May 27
Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns
Summary Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss. The obesity treatment market is expected to grow exponentially, reaching $77 billion by 2030, creating a significant opportunity for Altimmune. Altimmune needs to find a partnership to compete with established players like Novo Nordisk and Eli Lilly, but the potential of Pemvidutide is high, making it a buy. Read the full article on Seeking AlphaSeeking Alpha • Apr 12
Buy Altimmune's Potential Market Disruption With Pemvidutide
Summary Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Their lead drug candidate, Pemvidutide, targets glucagon-like peptide-1 and glucagon receptors to produce weight loss with reduced side effects. Pemvidutide has shown promising results in clinical trials for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and the company is seeking partnerships for further development. ALT's strategic shift includes partnering discussions to enhance Pemvidutide's development pathway and potential commercialization. Overall I think ALT is a viable investment for investors who are aware of the inherent risks in biotech. Read the full article on Seeking AlphaSeeking Alpha • Mar 27
Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Summary Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said that the GLP-1 market could exceed $100 billion by 2030. Results from the phase 2b IMPACT study, using pemvidutide for the treatment of patients with MASH, expected to be released Q1 of 2025. Altimmune had $198 million in cash as of December 31st of 2023; It will likely have to continue to tap into the ATM agreement or find another way to raise cash to fund its pipeline. Read the full article on Seeking AlphaSeeking Alpha • Feb 27
Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Summary Altimmune's stock price has experienced extreme volatility, but jumped by >20% yesterday due to the potential of pemvidutide, a drug candidate for obesity and liver disease. Some analysts believe pemvidutide can have a similar impact as Eli Lilly's tirzepatide and Novo Nordisk's semaglutide on these two indications - both Pharma's share prices have been soaring. Altimmune's previous COVID and anthrax vaccine efforts were unsuccessful, but there is optimism - based on some promising data - that pemvidutide could be different and provide a valuable opportunity. Ultimately, however, with its drug having some problematic side effects and the company struggling for funding, I'm giving Altimmune the thumbs down. There is a data readout in relation to a Hepatitis B therapy due this quarter - a small hedge against pemvidutide struggles - many will disagree, but selling after the recent bull run may be the right option. Read the full article on Seeking AlphaSeeking Alpha • Feb 12
Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Summary Altimmune's stock surged after revealing promising obesity treatment data for pemvidutide, a GLP-1/glucagon agonist, despite existing competition. Pemvidutide demonstrated dose-dependent weight loss in Phase 2, but high adverse event rates, especially gastrointestinal, led to notable discontinuation. Financially, Altimmune holds a strong current ratio with a 21-month runway despite the need for future capital to sustain operations. Investment Recommendation: Hold ALT stock due to the balance between pemvidutide's potential and its competition, tolerability concerns, and financial health. Read the full article on Seeking Alpha分析記事 • Feb 10
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Jan 10
Thoroughly Derisked, Altimmune Is Now A Great Buy
Summary Altimmune's weight loss drug, Pemvidutide, showed promising results in a phase 2 trial, with a mean weight loss of 15.6% at week 48. The drug also demonstrated better CV risk reduction, lipid changes and tolerability than its competitors, semaglutide and tirzepatide. Altimmune's stock is undervalued compared to the potential market success of a weight loss drug, with potential for significant upside. Read the full article on Seeking Alpha分析記事 • Oct 11
Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...財務状況分析
短期負債: ALTの 短期資産 ( $334.7M ) が 短期負債 ( $11.3M ) を超えています。
長期負債: ALTの短期資産 ( $334.7M ) が 長期負債 ( $40.3M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: ALT総負債よりも多くの現金を保有しています。
負債の削減: ALTの負債対資本比率は、過去 5 年間で0%から12.2%に増加しました。
貸借対照表
キャッシュ・ランウェイ分析
過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。
安定したキャッシュランウェイ: ALTは、現在の フリーキャッシュフロー に基づき、3 年以上にわたって十分な キャッシュランウェイ を有しています。
キャッシュランウェイの予測: ALTは、フリー キャッシュ フローが毎年10.8 % の歴史的率で減少し続ける場合、 2.6年間十分なキャッシュ ランウェイを有しています。
健全な企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/28 00:16 |
| 終値 | 2026/07/28 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Altimmune, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18
| アナリスト | 機関 |
|---|---|
| Eliana Merle | Barclays |
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |